Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Learns By Doing In Using REMS Powers; Guidance In “Future”

Executive Summary

FDA decisions on whether to require a risk evaluation and mitigation strategy for a new drug will continue to be made on a case-by-case basis while the agency gains on-the-job experience in interpreting requirements of the FDA Amendments Act
Advertisement

Related Content

GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk
Waking Up To REMS: Sponsors Should Test Risk Management In Phase III
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
Advertisement
UsernamePublicRestriction

Register

PS049837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel